UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR Classification Code Number) (I.R.S. Employer Identification Number) 4300 El Camino Real, Suite 210 Los Altos, CA 94022 (650) 351-4495 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: ...

Financial Performance - For the three months ended March 31, 2022, total operating expenses increased to approximately $3.5 million, a 384% increase from $731,000 in the same period in 2021[123] - The net loss for the three months ended March 31, 2022, was $3.5 million, a 267% increase from a net loss of $964,000 in the same period in 2021[123] - As of March 31, 2022, the accumulated deficit stood at $19.5 million, indicating ongoing financial challenges[129] - For the three months ended March 31, 2022, net cash used in operating activities was $2.957 million, primarily due to development costs and corporate expenditures[143] - The company incurred a net loss of $3.5 million for the three months ended March 31, 2022, after accounting for non-cash adjustments[143] - The company had no cash flows from financing activities for the three months ended March 31, 2022, compared to $820,000 in the same period of 2021[146] Operating Expenses - Research and development expenses rose to approximately $1.9 million, reflecting a 330% increase from $450,000 for the three months ended March 31, 2021, primarily due to increased drug development costs[124] - General and administrative expenses increased by 471% to approximately $1.6 million from $281,000 for the same period in 2021, driven by higher insurance and labor costs[125] Funding and Capital Needs - The company raised approximately $22.3 million in net proceeds from its IPO on July 15, 2021, intended for clinical studies and regulatory filings[128] - The company expects to require additional funding before the end of Q2 2023 to sustain operations and meet future expenditures[131] - The company anticipates needing to raise substantial additional capital, influenced by factors such as drug discovery efforts, clinical trials, and regulatory reviews[133] - The company issued convertible notes in 2021 totaling approximately $1,098,000, with a 12% annual interest rate, maturing between January and May 2022[137] - The company may need to delay or terminate development programs if it fails to raise necessary capital[135] Business Model and Development - The company’s business model focuses on licensing technologies and drugs for development and commercialization in global markets[109] - The company is developing two novel therapies: Renazorb for hyperphosphatemia in chronic kidney disease and UNI 494 for acute kidney injury[106] Impact of COVID-19 - The COVID-19 pandemic has introduced uncertainties that may delay clinical trials and increase costs, impacting the company's financial condition[115] Agreements and Accounting - The company plans to amend its Service Agreement with Globavir to reflect a reduced service fee of $6,000 per month[136] - The company accounted for the 2021 and 2020 Notes as stock-settled debt, accruing the carrying amount to the settlement amount through maturity[138][140] - The company has chosen to take advantage of the extended transition periods under the JOBS Act for complying with new accounting standards[155]

Financial Performance - The company reported a net loss of $10.0 million for the year ended December 31, 2021, compared to a net loss of $2.3 million for the year ended December 31, 2020, representing a 342% increase in losses [318]. - As of December 31, 2021, the company had an accumulated deficit of $15.9 million and expects to incur substantial additional losses in the future [325]. - Net cash used in operating activities was $5.8 million for the year ended December 31, 2021, primarily due to development costs and corporate expenditures [339]. - The company incurred a net loss of $10.0 million for the year ended December 31, 2021, after accounting for non-cash adjustments [339]. - The company experienced a loss of $431,000 due to the conversion of approximately $2.4 million of principal and $191,000 of unpaid accrued interest related to convertible notes [337]. Research and Development - Research and development expenses increased by approximately $5.1 million, or 499%, from $1.0 million in 2020 to $6.1 million in 2021, primarily due to increased development costs and non-cash expenses [319]. - Research and development expenses include costs for third-party services, consulting, and personnel-related expenses, with no material changes in accounting policies from 2020 to 2021 [344][345]. Operating Expenses - General and administrative expenses rose by approximately $1.9 million, or 188%, from $1.0 million in 2020 to $2.9 million in 2021, driven by higher insurance and labor costs [320]. - The company expects its operating expenses to increase significantly as it advances its product candidates through development and seeks regulatory approval [304]. Capital and Funding - The company raised approximately $22.3 million in net proceeds from its IPO on July 15, 2021, which will be used for pre-clinical and clinical studies, regulatory filings, and general corporate purposes [324]. - The company has funded its operations primarily through the sale of common stock and convertible notes, with a total of $1.1 million raised through convertible notes in 2021 [323]. - The company anticipates needing to raise substantial additional capital, influenced by factors such as drug discovery efforts, clinical trials, and regulatory reviews [327]. - Net cash provided by financing activities was $22.4 million for the year ended December 31, 2021, mainly from proceeds of the IPO [342]. - The company issued convertible notes totaling $1.1 million in 2021, with a 12% annual interest rate, maturing between January and May 2022 [332]. Business Model and Market - The company’s business model focuses on licensing technologies and drugs, with an emphasis on developing treatments for kidney diseases, specifically hyperphosphatemia and acute kidney injury [300]. - The number of patients with end-stage renal disease in the US is projected to reach between 971,000 and 1,259,000 by 2030, indicating a growing market for the company's products [301]. Third-Party Services - The company plans to continue using third-party service providers for pre-clinical and clinical development, as well as for manufacturing and supply [307]. Accounting and Compliance - The company has chosen to take advantage of the extended transition periods under the JOBS Act for complying with new accounting standards [352]. - The company paid Globavir $10,000 per month starting January 1, 2020, for administrative and consulting services, with service fee expenses recorded as general and administrative expenses [331].

| --- | --- | --- | |-------|-------|----------------------| | | | NASDAQ: UNCY | | | | Novel Treatments | | | | for Kidney Diseases | | | | Company Presentation | | | | February 2022 | LALIA LINE Forward Looking Statements This presentation contains certain "forward-looking" statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-40582 UNICYCIVE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of in ...

LLALLOULE | --- | --- | --- | --- | |-------|-------|----------------------|-------| | | | | | | | | Novel Treatments | | | | | for Kidney Diseases | | | | | Company Presentation | | | | | September 2021 | | Forward Looking Statements This presentation contains certain "forward-looking" statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-40582 WASHINGTON, D.C. 20549 FORM 10-Q UNICYCIVE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorpo ...